Shots:
MAIA Biotechnology has reported P-II (THIO-101) trial data assessing ateganosine followed by Libtayo (cemiplimab) in pts with advanced NSCLC who progressed after ≥2 SoC therapy regimens
As of Jun 30,…
15
15
12
12
12
12
12
12
12
11
